Meryl Cruz

Ms. Meryl Cruz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
LZLun Zhang
Lun Zhang
JZJiamin Zheng
Jiamin Zheng
MJMathew Johnson
Mathew Johnson
RMRupasri Mandal
Rupasri Mandal
MCMeryl Cruz
Meryl Cruz
David Scott WishartDavid Scott Wishart
David Scott Wishart
Background/Objectives: Targeted metabolomics is often criticized for the limited metabolite coverage that it offers. Indeed, most targeted assays developed or used by researchers measure fewer than 200 metabolites. In an effort to both expand the coverage and improve the accuracy of metabolite quantification in targeted metabolomics, we decided to develop a comprehensive liquid chromatography–tandem mass spectrometry (LC–MS/MS) assay that could quantitatively measure more than 700 metabolites in serum or plasma. Methods: The developed assay makes use of chemical derivatization followed by reverse phase LC–MS/MS and/or direct flow injection MS (DFI–MS) in both positive and negative ionization modes to separate metabolites. Multiple reaction monitoring (MRM), in combination with isotopic standards and multi-point calibration curves, is used to detect and absolutely quantify the targeted metabolites. The assay has been adapted to a 96-well plate format to enable automated, high-throughput sample analysis. Results: The assay (called MEGA) is able to detect and quantify 721 metabolites in serum/plasma, covering 20 metabolite classes and many commonly used clinical biomarkers. The limits of detection were determined to range from 1.4 nM to 10 mM, recovery rates were from 80% to 120%, and quantitative precision was within 20%. LC–MS/MS metabolite concentrations of the NIST® SRM®1950 plasma standard were found to be within 15% of NMR quantified levels. The MEGA assay was further validated in a large dietary intervention study. Conclusions: The MEGA assay should make comprehensive quantitative metabolomics much more affordable, accessible, automatable, and applicable to large-scale clinical studies.

5 August 2020 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
MCMeryl Cruz
Meryl Cruz
BPBenjamin J. Place
Benjamin J. Place
LWLaura J. Wood
Laura J. Wood
AUAaron Urbas
Aaron Urbas
AWAndrzej Wasik
Andrzej Wasik
WRWerickson Fortunato de Carvalho Rocha
Werickson Fortunato de Carvalho Rocha

8 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EAEnrique Almanza-Aguilera
Enrique Almanza-Aguilera
Miriam Martínez-HuélamoMiriam Martínez-Huélamo
Miriam Martínez-Huélamo
YLYamile Lopez
Yamile Lopez
DFDaniel Guiñón Fort
Daniel Guiñón Fort
AGAnna Guadall
Anna Guadall
Raul Zamora-RosRaul Zamora-Ros
Raul Zamora-Ros
Background and Objective: Nutrimetabolomics may reveal novel insights into early metabolic alterations and the role of dietary exposures on prostate cancer (PCa) risk. We aimed to prospectively investigate the associations between plasma metabolite concentrations and PCa risk, including clinically relevant tumor subtypes. Methods: We used a targeted and large-scale metabolomics approach to analyze plasma samples of 851 matched PCa case–control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Associations between metabolite concentrations and PCa risk were estimated by multivariate conditional logistic regression analysis. False discovery rate (FDR) was used to control for multiple testing correction. Results: Thirty-one metabolites (predominately derivatives of food intake and microbial metabolism) were associated with overall PCa risk and its clinical subtypes (p < 0.05), but none of the associations exceeded the FDR threshold. The strongest positive and negative associations were for dimethylglycine (OR = 2.13; 95% CI 1.16–3.91) with advanced PCa risk (n = 157) and indole-3-lactic acid (OR = 0.28; 95% CI 0.09–0.87) with fatal PCa risk (n = 57), respectively; however, these associations did not survive correction for multiple testing. Conclusions: The results from the current nutrimetabolomics study suggest that apart from early metabolic deregulations, some biomarkers of food intake might be related to PCa risk, especially advanced and fatal PCa. Further independent and larger studies are needed to validate our results.

17 August 2026 in Food & Function
Verified
Journal Article
Open access
MCMeryl Cruz
Meryl Cruz
Miriam Martínez-HuélamoMiriam Martínez-Huélamo
Miriam Martínez-Huélamo
EYElena Yubero-Serrano
Elena Yubero-Serrano
MCMarta Cubedo
Marta Cubedo
Marina Mora-OrtizMarina Mora-Ortiz
Marina Mora-Ortiz
TMTomas Meroño
Tomas Meroño
The Mediterranean diet (MD) increased pyruvate, acetoacetate and TCA intermediate levels, and restored BCAA metabolism. Some of these changes related to metabolic flexibility were associated with improved cognition in older adults with MCI.